Understand the gynecology partnering landscape using intelligence from 155 real-world collaboration and licensing deals.
Gynecology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 155 partnering deals involving gynecology assets, technologies and development programs.
Gynecology partnering spans a specialist and evolving area of women’s health, encompassing a range of therapeutic indications, technologies and development strategies.
The report brings this activity together in one resource, enabling users to understand who is partnering, which gynecology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in gynecology and women’s health partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and identify transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Identify comparable gynecology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking women’s health opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable gynecology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building women’s health portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying gynecology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Gynecology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 155 partnering deals involving gynecology assets, technologies and development programs.
Gynecology partnering spans a specialist and evolving area of women’s health, encompassing a range of therapeutic indications, technologies and development strategies.
The report brings this activity together in one resource, enabling users to understand who is partnering, which gynecology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in gynecology and women’s health partnering.
Understand the gynecology partnering landscape
The report analyzes gynecology dealmaking from 2016 to 2026, including:
- Trends in gynecology partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active gynecology dealmakers
- Leading deals by disclosed value
- How gynecology partnering activity is evolving
Benchmark gynecology deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading gynecology dealmakers and prospective partners
The report identifies the most active companies in gynecology partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking gynecology and women’s health opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in particular technologies or approaches
- Competitors pursuing related external innovation strategies
Compare partnering activity across therapeutic indications and targets
Gynecology encompasses a range of distinct therapeutic opportunities with differing clinical, competitive and commercial dynamics.The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and identify transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how gynecology agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected gynecology transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive gynecology deal directory
The report includes a comprehensive directory of 155 gynecology collaboration and licensing deals, providing a focused resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication or target
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable gynecology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking women’s health opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable gynecology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building women’s health portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide gynecology intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying gynecology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in gynecology dealmaking
Chapter 3 - Financial deal terms for gynecology partnering
Chapter 4 - Leading gynecology deals and dealmakers
Chapter 5 - Gynecology contract document directory
Chapter 6 - Gynecology dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 23andMe
- Aarhus University
- Abbott Laboratories
- Abbvie
- Accord Healthcare
- Acerus
- Ache
- AdaptivEndo
- Advaxis
- Adynxx
- AIMA Laboratories
- AIVF
- Allakos
- Allegheny Technologies
- Altavant Sciences
- Amag Pharmaceuticals
- American Dental Association
- Amring Pharmaceuticals
- AntibioTx
- ApolloBio
- Aptorum Group
- Ascend Therapeutics
- Asieris MediTech
- ASKA Pharmaceuticals
- Aspen Pharmacare Canada
- ASPiRA Labs
- AstraZeneca
- Auransa
- Avion Pharmaceuticals
- Avomeen
- Bayer
- Besins Healthcare
- Bill and Melinda Gates Foundation
- Biofourmis
- BioGen Medical
- BioNano Genomics
- BioPep
- BioSyent Pharma
- BioVaxys
- Bloom Fertility
- BMV Medica
- Brigham and Women's Hospital
- California Cryobank
- Cancer Prevention and Research Institute of Texas
- Celmatix
- Chinese Academy of Sciences
- Chugai Pharmaceutical
- Cicero Diagnostics
- Co-Diagnostics
- Cocrystal Pharma
- Cognizant
- Colorado Center for Reproductive Medicine
- Conceptions Reproductive Associates of Colorado
- Conduit Pharmaceuticals
- ConTipi
- Control Flo Medical
- Coriell Life Sciences
- Cosette Pharmaceuticals
- CR Pharma
- CryoPort
- Dare Bioscience
- Department of Defense
- Dewpoint Therapeutics
- Duke University
- Easton Pharmaceuticals
- Embr Labs
- Emory University
- EndoCeutics
- Enzyvant Science
- Especificos Stendhal
- Eurofins LifeCodexx
- European Board and College of Obstetrics and Gynaecology
- European Wellness Biomedical Group
- Evidation Health
- Evotec
- Evvy
- Exeltis
- Expedeon
- ExSeed
- Ferring Pharmaceuticals
- Flo Health
- Foresee Pharmaceuticals
- Fujifilm Irvine Scientific
- Fuji Pharma
- Gameto
- Gedeon Richter
- Genea Biomedx
- Genetiks
- Genome Medical
- Genomic Prediction
- German Cancer Research Center
- Gilead Sciences
- GOG Foundation
- Good Start Genetics
- Granata Bio
- Guided Therapeutics
- Gynica
- Halt Medical
- Hammock Pharmaceuticals
- Health Decisions
- HealthNet
- Helix
- Helix BioPharma
- Highmark Health
- Hologic
- Hope Medicine
- Hyloris Pharmaceuticals
- IBSA Group
- iGenomix
- Igyxos
- Illumina
- Inception Fertility
- Indegene Lifesystems
- InnerOptic Technology
- Innovative Health Diagnostics
- Inovio Pharmaceuticals
- Inserm Transfert
- INVO Bioscience
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Johns Hopkins University
- Karolinska Institute
- KinoPharma
- Knight Therapeutics
- LifeMD
- LinKinVax
- LUCA Science
- Lumir Lab
- Lyfe Medical
- mAbXience
- Massachusetts General Hospital
- Mayne Pharma
- MD Anderson Cancer Center
- MDNA Life Sciences
- Medinova
- Meitheal Pharmaceuticals
- Menarini
- MenoGeniX
- Merck and Co
- Merck KGaA
- Microbix Biosystems
- MicroGenDX
- MilanaPharm
- Millendo Therapeutics
- Millicent Pharma
- Milu Labs
- Mithra Pharmaceuticals
- Monash IVF
- Morphic Therapeutic
- Mundipharma
- MyBiotics Pharma
- Mycovia Pharmaceuticals
- Myovant Sciences
- Nanjing King-friend Biochemical Pharmaceutical
- National Human Genome Research Institute
- National Institute of Child Health and Human Development
- National Institute on Aging
- National Institutes of Health
- Novan
- NuProbe
- NX Prenatal
- ObsEva
- OmniVision Technologies
- OncoNano Medicine
- One Drop
- Organon
- Osel
- Osivax
- Osteolabs
- Ovation
- Oviva Therapeutics
- OvuSense
- Palatin Technologies
- PaxGenBio
- PDS Biotechnology
- Pfizer
- PharmaJet
- Pharmanest
- Phase Genomics
- Photocure ASA
- Pierre Fabre
- Pinnacle Fertility
- PolarisQB
- Predictive Technology Group
- Procare Health
- Psyche Systems
- Purna Pharmaceuticals
- QIAGEN
- Radius Health
- Rebiotix
- ReproCell
- Roivant Sciences
- Royal Philips Electronics
- Scholar Rock
- Searchlight Pharma
- Selexis
- Sema4
- Shandong Yaohua Medical Instrument
- Sharp Corporation
- Shenghuo Medical
- Skive Hospital
- Starpharma
- Statens Serum Institute
- StemCyte
- St George Street Capital
- Strainprint Technologies
- Sumitomo Dainippon Pharma
- Sumitovant Biopharma
- Sun Pharmaceutical
- Syneos Health
- SynteractHCR
- Systems Oncology
- Takeda Pharmaceutical
- Tessa Therapeutics
- Texas A&M University
- Theramex
- TherapeuticsMD
- Thermo Fisher Scientific
- TiumBio
- TMRW Life Sciences
- Transgene
- twoXAR
- Ulisse Biomed
- University of Antwerp
- University of Illinois
- University of Leuven
- University of Oxford
- UpScriptHealth
- Urovant Sciences
- Vaccibody
- Valeo Pharma
- Veritas
- Viatris
- VICHY Laboratoires
- Viramal
- VirtaMed
- Vitro Biopharma
- Woom
- Xbrane Biopharma
- Xisle Pharma Ventures Trust
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
